Awards & Advancement

GenSight Biologics appoints Mohamed Genead as chief medical officer

Thursday, May 4, 2017

GenSight Biologics, a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, announced it has appointed Mohamed Genead, M.D., as chief medical officer. Dr. Genead brings more than 15 years of experience to the role, including his most recent role as vice president & global therapeutic area head for Ophthalmology/Retina Gene Therapy at Biogen.

[Read More]

CureVac appoints Daniel Menichella as CEO of U.S. Subsidiary

Wednesday, May 3, 2017

CureVac AG, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based therapies, has announced the appointment of Daniel Menichella as CEO of CureVac Inc., its Boston-based U.S. subsidiary. Menichella, an experienced executive in the biotech industry, will develop CureVac’s U.S. organization with a clear focus on business and corporate development activities around CureVac’s versatile mRNA technology platform.

[Read More]

H3 Biomedicine appoints Lihua Yu chief data sciences officer

Tuesday, May 2, 2017

H3 Biomedicine, a clinical stage biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of Eisai’s global Oncology Business Group, announced that Lihua Yu, Ph.D., has been promoted to chief data sciences officer (CDSO). Dr. Yu previously served as H3 Biomedicine’s vice president, Data Science and Information Technology.

[Read More]

SynteractHCR adds three senior executives to management team

Thursday, April 20, 2017

SynteractHCR, a full-service, international CRO, has appointed three new senior-level managers to its leadership team to ensure internationally-cohesive, enhanced support for sponsors. SynteractHCR’s newest senior executives include: Heather Davis, executive director of U.S. Project Management; Zia Haque, executive director, Clinical Data Management, and John Whitaker, Ph.D. as executive director, Biostatistics. All will report to Marlo M. Vasquez, vice president, U.S. Operations at SynteractHCR.

[Read More]